#IASO_Bio

Thiard News@F4F

@newsen.bsky.social

3 months ago

IASO Bio Shares Promising Updates for CAR-T Therapy in Multiple Myeloma at 2025 ASH IASO Bio introduced new clinical results for their CAR-T therapy, Equecabtagene Autoleucel (Eque-cel), for high-risk multiple myeloma patients at ASH 2025.

IASO Bio Shares Promising Updates for CAR-T Therapy in Multiple Myeloma at 2025 ASH #China #Shanghai #CAR-T_therapy #Multiple_Myeloma #IASO_Bio

Thiard News@F4F

@newsen.bsky.social

3 months ago

IASO Biotechnology's Fucaso Therapy Receives BLA Approval for Advanced Multiple Myeloma Treatment IASO Bio's Fucaso therapy, approved by Hong Kong's Department of Health, treats relapsed multiple myeloma. This marks a significant milestone for China-developed therapies.

IASO Biotechnology's Fucaso Therapy Receives BLA Approval for Advanced Multiple Myeloma Treatment #China #Hong_Kong #CAR-T_therapy #IASO_Bio #FUCASO

Thiard News@F4F

@newsen.bsky.social

4 months ago

IASO Bio Teams Up with GC Cell to Enhance CAR-T Therapy Access in Korea IASO Bio has partnered with GC Cell to launch the CAR-T therapy Fucaso in Korea, aiming to improve treatment options for multiple myeloma patients. The collaboration seeks to enhance accessibility through competitive pricing.

IASO Bio Teams Up with GC Cell to Enhance CAR-T Therapy Access in Korea #Nanjing #South_Korea #CAR-T_therapy #IASO_Bio #GC_Cell

Thiard News@F4F

@newsen.bsky.social

4 months ago

IASO Bio's Innovative CAR-T Therapy Shows Promise for Multiple Myeloma Patients IASO Biotherapeutics announces significant results for RD118, its anti-GPRC5D CAR-T therapy, offering hope for multiple myeloma patients with few options left.

IASO Bio's Innovative CAR-T Therapy Shows Promise for Multiple Myeloma Patients #China #Shanghai #IASO_Bio #CAR-T #GPRC5D

Thiard News@F4F

@newsen.bsky.social

5 months ago

IASO Bio Showcases Impressive Three-Year Results of CAR-T Therapy for Multiple Myeloma at IMS 2025 IASO Bio revealed notable three-year follow-up findings for its CAR-T therapy, Fucaso, for treating multiple myeloma at the 2025 IMS Annual Meeting, showing strong long-term efficacy.

IASO Bio Showcases Impressive Three-Year Results of CAR-T Therapy for Multiple Myeloma at IMS 2025 #China #Shanghai #CAR-T_therapy #IASO_Bio #FUCASO

Thiard News@F4F

@newsen.bsky.social

6 months ago

IASO Bio to Showcase Innovative CAR-T Therapy Findings for MS at Major Conferences in 2025 IASO Bio is set to present its groundbreaking anti-BCMA CAR-T cell therapy Equecabtagene Autoleucel for Multiple Sclerosis at the renowned ANA and ECTRIMS events in 2025.

IASO Bio to Showcase Innovative CAR-T Therapy Findings for MS at Major Conferences in 2025 #USA #Baltimore #CAR-T_therapy #IASO_Bio #Equecabtagene

Thiard News@F4F

@newsen.bsky.social

8 months ago

Breakthrough Efficacy of Equecabtagene Autoleucel Presented at EAN Congress for MS Treatment At the 11th EAN Congress, IASO Bio showcased promising results from a study on Equecabtagene Autoleucel, an innovative MS therapy, indicating significant improvements in patient conditions.

Breakthrough Efficacy of Equecabtagene Autoleucel Presented at EAN Congress for MS Treatment #China #Shanghai #Multiple_Sclerosis #IASO_Bio #Equecabtagene

Thiard News@F4F

@newsen.bsky.social

9 months ago

IASO Bio Marks Significant Milestones with New R&D Center and Forum in Shanghai IASO Biotherapeutics celebrates the inauguration of its Global R&D Center in Shanghai, emphasizing advancements in cell therapy and strategic partnerships for international commercialization.

IASO Bio Marks Significant Milestones with New R&D Center and Forum in Shanghai #China #Shanghai #IASO_Bio #Cell_Therapy #R&D_Center

Thiard News@F4F

@newsen.bsky.social

11 months ago

IASO Bio's Equecabtagene Autoleucel Receives Approval in Macau - A Milestone for Cell Therapies IASO Biotherapeutics celebrates the Macau approval of Equecabtagene Autoleucel, a groundbreaking CAR-T therapy for multiple myeloma patients.

IASO Bio's Equecabtagene Autoleucel Receives Approval in Macau - A Milestone for Cell Therapies #China #CAR-T_therapy #Macao #IASO_Bio #Equecabtagene

Thiard News@F4F

@newsen.bsky.social

1 year ago

IASO Bio’s Equecabtagene Autoleucel Secures Regulatory Green Light in Hong Kong IASO Biotherapeutics has received acceptance for its New Drug Application for Equecabtagene Autoleucel, a CAR-T therapy for relapsed multiple myeloma, from Hong Kong health authorities.

IASO Bio’s Equecabtagene Autoleucel Secures Regulatory Green Light in Hong Kong #China #Hong_Kong #CAR-T_therapy #IASO_Bio #FUCASO

Thiard News@F4F

@newsen.bsky.social

1 year ago

IASO Bio's New Drug Application Acceptance Marks Milestone for FUCASO in Singapore IASO Bio's Equecabtagene Autoleucel (FUCASO) receives NDA acceptance from Singapore's HSA, marking a significant step in CAR-T therapy expansion.

IASO Bio's New Drug Application Acceptance Marks Milestone for FUCASO in Singapore #Singapore #IASO_Bio #Equecabtagene #FUCASO

Thiard News@F4F

@newsen.bsky.social

1 year ago

New Insights on CAR T-Cell Therapy Effectiveness: Study by IASO Bio at 2024 ASH Annual Meeting IASO Bio unveils key study findings on CAR T-Cell persistence in treating relapsed/refractory multiple myeloma at the 2024 ASH meeting, emphasizing implications for future therapies.

New Insights on CAR T-Cell Therapy Effectiveness: Study by IASO Bio at 2024 ASH Annual Meeting #China #Shanghai #Multiple_Myeloma #IASO_Bio #CAR_T-Cell